CytomX Therapeutics (CTMX) News Today $3.26 -0.04 (-1.21%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.33 +0.07 (+2.12%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Will CytomX Therapeutics’ (CTMX) New Business Chief Reshape Its Growth Strategy or Reinforce Stability?October 22 at 2:27 AM | finance.yahoo.com3CTMX : CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)October 21, 2025 | benzinga.comBarclays Maintains CytomX Therapeutics (CTMX) Overweight RecommendationOctober 21, 2025 | msn.comCytomX Therapeutics price target raised to $6 from $3.50 at BarclaysOctober 21, 2025 | msn.comCytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year High - Still a Buy?October 21, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Up 15.5% - Here's What HappenedOctober 20, 2025 | marketbeat.comCytomX Therapeutics Appoints Rachael Lester as Senior Vice President, Chief Business OfficerOctober 20, 2025 | quiverquant.comQCytomX Therapeutics Appoints Rachael Lester as Chief Business OfficerOctober 20, 2025 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Buy" by BrokeragesOctober 17, 2025 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year High - What's Next?October 15, 2025 | marketbeat.comOppenheimer positive on CytomX after Merus colon cancer dataOctober 14, 2025 | msn.comCytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is PossibleOctober 13, 2025 | seekingalpha.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Buy" by AnalystsOctober 12, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Down 7% - Should You Sell?October 11, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Hits New 52-Week High After Analyst UpgradeOctober 10, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Raised to "Hold (C-)" at Weiss RatingsOctober 9, 2025 | marketbeat.comCytomX: A Fresh Start With New Drugs After Total Pipeline FailureOctober 6, 2025 | seekingalpha.comCytomX Therapeutics (NASDAQ:CTMX) Stock Price Down 3.8% - Should You Sell?October 3, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week High - Time to Buy?September 30, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Up 8.5% - Should You Buy?September 29, 2025 | marketbeat.comWhy CytomX Therapeutics Stock Was Skyrocketing This WeekSeptember 26, 2025 | msn.comCantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight RecommendationSeptember 23, 2025 | msn.comCantor Fitzgerald Forecasts CTMX FY2025 EarningsSeptember 23, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Raised to Strong-Buy at Cantor FitzgeraldSeptember 23, 2025 | marketbeat.comTop 5 Oncology Stocks to Watch According to BarclaysSeptember 22, 2025 | au.investing.comCytomX Therapeutics initiated with an Overweight at Cantor FitzgeraldSeptember 22, 2025 | msn.comCongress Park Capital LLC Sells 578,264 Shares of CytomX Therapeutics, Inc. $CTMXSeptember 21, 2025 | marketbeat.comBarclays Upgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong-BuySeptember 19, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of "Buy" by AnalystsSeptember 18, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Given "Overweight" Rating at BarclaysSeptember 18, 2025 | marketbeat.comCytomX Therapeutics (CTMX) Gets a Buy from OppenheimerSeptember 18, 2025 | theglobeandmail.comCytomX Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comCytomX Therapeutics assumed with an Overweight at BarclaysSeptember 16, 2025 | msn.comJacobs Levy Equity Management Inc. Trims Stock Position in CytomX Therapeutics, Inc. $CTMXSeptember 15, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Pass Below 50-Day Moving Average - Should You Sell?September 13, 2025 | marketbeat.comCytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comRA Capital Management L.P. Purchases New Shares in CytomX Therapeutics, Inc. $CTMXSeptember 4, 2025 | marketbeat.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)?August 30, 2025 | finance.yahoo.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50-Day Moving Average - Should You Sell?August 30, 2025 | marketbeat.comCytomX Therapeutics to Present at Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comCytomX Therapeutics Updates on CX-2051 Phase 1 StudyAugust 15, 2025 | msn.comFY2026 EPS Forecast for CytomX Therapeutics Cut by AnalystAugust 15, 2025 | marketbeat.comCytomX trial ongoing despite grade five event, says OppenheimerAugust 13, 2025 | msn.comHC Wainwright Issues Negative Outlook for CTMX EarningsAugust 13, 2025 | marketbeat.comCytomX Therapeutics Provides Update on CX-2051 Phase 1 StudyAugust 13, 2025 | globenewswire.comCytomX Therapeutics Earnings Call: Clinical Progress and Financial StrengthAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCytomX Therapeutics: Updated Outlook For Late 2025August 8, 2025 | seekingalpha.comCytomX (CTMX) Q2 Revenue Drops 26%August 7, 2025 | fool.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.500.93▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼103▲CTMX Articles Average Week Get the Latest News and Ratings for CTMX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ocular Therapeutix News Today ANI Pharmaceuticals News Today Vera Therapeutics News Today Cogent Biosciences News Today Stoke Therapeutics News Today Vericel News Today Arcus Biosciences News Today Tilray Brands News Today Twist Bioscience News Today Immunocore News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
